The Apex Times
Above the Noise
Business Wire
BusinessMeta and Alphabet’s exposure to Jio Platforms faces a valuation test as India’s IPO hype buildsThe Apex TimesBusinessCathie Wood’s Ark cuts AMD in a $124 million shift within its AI stock basket, Yahoo Finance reportsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessMeta and Alphabet’s exposure to Jio Platforms faces a valuation test as India’s IPO hype buildsThe Apex TimesBusinessCathie Wood’s Ark cuts AMD in a $124 million shift within its AI stock basket, Yahoo Finance reportsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessMeta and Alphabet’s exposure to Jio Platforms faces a valuation test as India’s IPO hype buildsThe Apex TimesBusinessCathie Wood’s Ark cuts AMD in a $124 million shift within its AI stock basket, Yahoo Finance reportsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessMeta and Alphabet’s exposure to Jio Platforms faces a valuation test as India’s IPO hype buildsThe Apex TimesBusinessCathie Wood’s Ark cuts AMD in a $124 million shift within its AI stock basket, Yahoo Finance reportsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex Times
Back to front
Eli Lilly files six more lawsuits tied to retatrutide black-market sales, as CMO warns the pills are not legitimate medicines
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 12, 8:55 AM EDT

Eli Lilly files six more lawsuits tied to retatrutide black-market sales, as CMO warns the pills are not legitimate medicines

The drugmaker says newly targeted sellers are offering products that are unverified and unapproved, and it is stepping up legal action aimed at limiting off-channel distribution of retatrutide.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Eli Lilly is taking additional legal steps aimed at what it describes as illegal sales of retatrutide outside approved channels. In a move that indicates an escalation in its enforcement posture, the company said it has brought six new lawsuits related to alleged black-market distribution tied to its weight-loss drug candidate.

Lilly’s central message is that the products being marketed are not genuine, and that people who buy them face heightened risks. In remarks attributed to the company, Lilly’s chief marketing officer, Matt Hyman, said the items sold in the black market are “not a medicine.”

According to the report, Lilly characterized the products as unverified and unapproved. The company’s position, as described in the post, is that the black-market offerings have not been evaluated through the regulatory process required for legitimate medicines, and therefore should not be treated as safe or comparable to anything Lilly is developing and distributing through medical oversight.

The six additional lawsuits appear to be part of an ongoing effort to intervene earlier and more aggressively against unauthorized sellers. While the report does not lay out specific details such as the jurisdictions involved, the identities of the targets, or the exact claims in each case, it frames the actions as a response to continued off-channel activity.

Retatrutide is a drug program associated with metabolic and weight-management goals, and Lilly has been seeking to build a robust pipeline around related therapies. The company has repeatedly faced a broader industry challenge as demand for weight-loss and metabolic drugs has surged, including the risk that unauthorized products circulate while legitimate supply and clinical access remain constrained.

Why It Matters

  • More lawsuits suggest Lilly is trying to curb secondary-market activity rather than relying only on public warnings.
  • If unauthorized sellers continue to operate, the reputational and safety risk to legitimate drug programs can grow, even when the legal target is “gray” or counterfeit distribution.
  • Enforcement pressure can also shape how clinics and consumers respond to online or off-channel offers for weight-management drugs.

Sources

Key Facts

  • Eli Lilly said it filed six new lawsuits related to alleged black-market sales tied to retatrutide.
  • Matt Hyman, Lilly’s chief marketing officer, described the black-market products as “not a medicine.”
  • Lilly said the products being sold on the black market are unverified and unapproved.
  • The report frames the lawsuits as an escalation in Lilly’s effort to reduce exposure to unauthorized retatrutide offerings.

Healthcare Related

Eli Lilly files six more lawsuits tied to retatrutide black-market sales, as CMO warns the pills are not legitimate medicines | The Apex Times